Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of bevacizumab + capecitabine + oxaliplatin as first-line treatment in elderly patients with metastatic colorectal adenocarcinoma
2009-010417-73Phase 2Active
- Sponsor
- GEMCAD
- Start
- Apr 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab, capecitabine and oxaliplatin in colorectal adenocarcinoma and colorectal cancer (CRC), sponsored by GEMCAD. Started Apr 2009; status: active.
02
Drugs
bevacizumabcapecitabineoxaliplatin
03
Conditions
colorectal adenocarcinomacolorectal cancer (CRC)
Beyond the preview
Go deeper on 2009-010417-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010417-73.